Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury

dc.citation.doi10.1016/j.bmcl.2014.01.016en_US
dc.citation.epage1061en_US
dc.citation.issue4en_US
dc.citation.jtitleBioorganic and Medicinal Chemistry Lettersen_US
dc.citation.spage1057en_US
dc.citation.volume24en_US
dc.contributor.authorPrior, Allan M.
dc.contributor.authorZhang, Man
dc.contributor.authorBlakeman, Nina
dc.contributor.authorDatta, Palika
dc.contributor.authorPham, Hung
dc.contributor.authorChen, Qian
dc.contributor.authorYoung, Lindon H.
dc.contributor.authorWeis, Margaret T.
dc.contributor.authorHua, Duy H.
dc.contributor.authoreidduyen_US
dc.date.accessioned2014-05-30T13:25:47Z
dc.date.available2014-05-30T13:25:47Z
dc.date.issued2014-02-15
dc.date.published2014en_US
dc.description.abstractVarious triacsin C analogs, containing different alkenyl chains and carboxylic acid bioisoteres including 4-aminobenzoic acid, isothiazolidine dioxide, hydroxylamine, hydroxytriazene, and oxadiazolidine dione, were synthesized and their inhibitions of long chain fatty acyl-CoA synthetase (ACSL) were examined. Two methods, a cell-based assay of ACSL activity and an in situ [¹⁴C]-palmitate incorporation into extractable lipids were used to study the inhibition. Using an in vivo leukocyte recruitment inhibition protocol, the translocation of one or more cell adhesion molecules from the cytoplasm to the plasma membrane on either the endothelium or leukocyte or both was inhibited by inhibitors 1, 9, and triacsin C. The results suggest that inhibition of ACSL may attenuate the vascular inflammatory component associated with ischemia reperfusion injury and lead to a decrease of infarct expansion.en_US
dc.identifier.urihttp://hdl.handle.net/2097/17802
dc.language.isoen_USen_US
dc.relation.urihttp://doi.org/10.1016/j.bmcl.2014.01.016en_US
dc.rightsThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectHydroxytriazeneen_US
dc.subjectIschemia reperfusion injuryen_US
dc.subjectLong chain fatty acyl-CoA synthetase (ACSL)en_US
dc.subjectInhibitorsen_US
dc.subjectOxadiazolidine dioneen_US
dc.subjectTriacsin Cen_US
dc.titleInhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injuryen_US
dc.typeArticle (author version)en_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
HuaBMCL2014.pdf
Size:
1.04 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.62 KB
Format:
Item-specific license agreed upon to submission
Description: